Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>

WealthTrust Axiom LLC Increases Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Financial News Live ·  {{timeTz}}

WealthTrust Axiom LLC increased its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) by 245.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 98,500 shares of the company's stock after buying an additional 70,000 shares during the period. WealthTrust Axiom LLC owned about 0.25% of Trevi Therapeutics worth $216,000 at the end of the most recent quarter.

Separately, Commonwealth Equity Services LLC acquired a new position in Trevi Therapeutics during the 1st quarter worth approximately $33,000. Institutional investors own 75.34% of the company's stock.

Get Trevi Therapeutics alerts:

Wall Street Analysts Forecast Growth

Several research firms have commented on TRVI. Needham & Company LLC boosted their price target on shares of Trevi Therapeutics from $8.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, June 29th. Oppenheimer boosted their price target on shares of Trevi Therapeutics to $12.00 in a report on Monday, July 4th.

Trevi Therapeutics Trading Up 7.7 %

Shares of Trevi Therapeutics stock opened at $3.91 on Friday. The company has a fifty day simple moving average of $2.92 and a 200-day simple moving average of $2.15. Trevi Therapeutics, Inc. has a 12-month low of $0.46 and a 12-month high of $4.09. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.32 and a current ratio of 2.32.

Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.07. During the same quarter last year, the firm posted ($0.43) earnings per share. As a group, equities analysts expect that Trevi Therapeutics, Inc. will post -0.81 earnings per share for the current year.

Insider Activity

In related news, major shareholder Tpg Gp A, Llc sold 46,128 shares of the stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $2.74, for a total transaction of $126,390.72. Following the completion of the sale, the insider now owns 4,754,721 shares in the company, valued at approximately $13,027,935.54. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 546,128 shares of company stock worth $1,572,283. Corporate insiders own 47.30% of the company's stock.

About Trevi Therapeutics

(Get Rating)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.

Further Reading

  • Get a free copy of the research report on Trevi Therapeutics (TRVI)
  • MarketBeat: Week in Review 8/1 – 8/5
  • How to Use High Beta Stocks to Maximize Your Investing Profits
  • Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
  • Beyond Meat Is Not Beyond Hope, And It's Cheap
  • Why Apple Could Be At All-Time Highs By Year End

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with's FREE daily email newsletter.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top